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Background:  To determine the efficacy and safety 
of topical 10% potassium hydroxide solution in the 
treatment of molluscum contagiosum (MC) .  
Methods: An  open,  prospective, non-randomized  
study  of  one year duration  was  conducted using  
10% KOH solution  to  treat  MC. Twenty eight 
patients completed the study. A total of seven 
appointments were planned; one baseline and six 
follow-up visits. 10% KOH was applied to 
molluscum lesions daily till the lesions resolved or 
till 3 months had elapsed.  
Results: Twenty eight patients, among which 22 
were children, completed the study. The mean age of 
patients was 10.6 years. The total lesion count in the 
patients varied from 5 – 94, with the mean lesion 
count of 22.14 SD +_ 18.32. There  was  complete  
resolution  of  lesions  in 20 (71.4%)  of  patients ,  4 
(14.3) had a near complete, 2 (7.1%) had partial and 2 
(7.1%) patients had no improvement.  82% patients 
tolerated the treatment well with no side effects. 
Conclusion:10% KOH solution is an effective and 
well tolerated treatment for MC. It is less painful 
and cost-effective as compared to many well-
established therapeutic modalities. It has the 
advantage of ease of application at home making it 
an acceptable and feasible option for the treatment 
of MC. 
Key Words: Molluscum contagiosum, Potassium 
hydroxide, Efficacy. 
Introduction 
Molluscum Contagiosum (MC) is among the most 
common viral skin infections. Common treatment 
options include destructive therapy, topical therapy 
and immunotherapy. Destructive therapy is poorly 
tolerated because of pain on application. In addition, 
these therapies are expensive and have inconvenience 
of application in hospital setting. MC  is  among  the  
most  common  viral  skin  infections ,  occurring  in  
approx  2-8% of  children.1,2 It is caused by a member 
of the Poxvirus family, the genus Molluscipox virus. 
The virus is transmitted by close physical contact, 
autoinoculation, and fomites.MC presents as 
asymptomatic, discrete, smooth, flesh-coloured, dome-
shaped papules with central umbilication.1 The lesions 
can be numerous and recurrent. The infection usually 
resolves within months in people without immune 
deficiency, but treatment may be preferred for social 
and cosmetic reasons or to avoid spreading the 
infection.3Treatment options include destructive 
therapy, topical therapy, immunotherapy and oral 
therapy.1 Destructive  treatment  modalities  include  
curettage,  cryotherapy, expression  or  pricking  with  
a  sterile  needle,  electrodesiccation, photodynamic  
therapy,  and laser  ablation.4,5Among topical therapies 
different chemical agents, like cantharidin,6 povidone-
iodine,7 potassium hydroxide,8 tretinoin,9 and 
imiquimod10  have been used with variable success. 
Immune modulating agents include interferon alpha, 
imiquimod and cimetidine.1 Destructive  therapy  is  
poorly  tolerated  in  children  because  of  pain  on 
application. In addition, these therapies are expensive 
and have inconvenience of application in hospital 
setting.   
Patients and Methods 
An  open,  prospective, non-randomized  study  of   
one year duration  was  conducted  at  Dermatology  
Department  of  Combined  Military  Hospital,  Lahore 
   using  10% KOH solution  to  treat  MC.  Sample size 
of 28 cases was estimated using 95% confidence 
interval and 14% deviation acceptance with a 
percentage of complete response in 85% in the 
previous studies.   A total of seven appointments were 
planned; one baseline and six follow-up visits. During 
the baseline visit thorough history and dermatological 
examination was carried out. Cases  were  studied  for 
 number  of  lesions, their  site, any eczematous 
change, presence of  pain or pruritus. First application 
of 10% KOH solution was performed with the patient 
or parent closely observing the procedure and was 
advised to apply the drug in a similar way at home 
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twice daily. Six follow-up visits were planned at the 
end of week 1, 2, 4, 6, 8 and 12. The medication was to 
be applied till the lesions resolved or till 3 months had 
elapsed. KOH applied on the skin initiates an 
inflammatory response leading to lesion clearance.   
The number  of  lesions, their  site,  crusting ,  
erythema ,  erosions , pain ,  pruritus ,  improvement  
of  lesion were documented. The clinical response to 
treatment was assessed using the methods devised by 
Marsalet al and Capriotti et al. 11,12  The patients were 
divided into 4 groups on the basis of improvement of 
MC lesions. Group 4= complete cure; Group 3= near 
complete response (with less than 5 MC lesions all 
over the body) ;Group 2= partial response (less than 
60% of the lesions since the baseline visit and 
more/equal than 5 lesions);Group 1= poor response 
(>60% of the lesions since baseline visit).  Patients 
whose lesions cleared up before 3 months were 
documented and were discharged from the study 
having attained “complete cure”. At the end of 3 
months final assessment was made . 
Results 
Twenty eight patients, 22 children and 6 adults 
completed the study. Age  of  patients  ranged  from  2 
 years  to  36  years  and  the  mean  age  was  10.6 
years ± 8.96. Eleven (39.3%) patients were female and 
17 (60.7%) were male. The duration of MC lesions 
varied from 2 – 39 weeks, with a mean duration of 8.6 
weeks (Table 1). Twelve (42.9%) of the patients gave 
positive family history in a first degree relative. The 
total lesion count in the patients varied from 5 – 94, 
with the mean lesion count of 22.14 SD +_ 18.32. 32.2% 
 patients  had  been  treated  previously with  other  
therapeutic  modality (17.9% with cryotherapy and 
14.3% with phenolization)  but  had  unsatisfactory  
response.  Successful 10% KOH solution application to 
MC initiates an inflammatory response consisting of 
erythema, crusting, erosion and usually associated 
with a mild stinging or pruritus(Figure 1).  There  was 
 complete  resolution  of  lesions  in 20 (71.4%)  of  
patients ,  4 (14.3%) had a near complete, 2 (7.1%) had 
partial and 2 (7.1%) patients had no improvement 
(Table 2). Complete cure was seen in majority of 
patients in age group2 to 20 years (Table 3;Figure 1-
4).Duration of disease could prolong the response time 
for the patients as it has strong effect on treatment and 
improvement in patients with a significant value 
(Table 4). There was no significant effect noted for 
other demographical factors like age, gender and site 
of disease. An equal distribution was observed on 
evaluation on different sites, but most commonly the 
lesions were present on multiple sites; 16(57%) of cases 
( 
Table 1:Distribution of the characteristics  
in study population (n=28) 
 Mean Percentages 
Age 10.60±8.96 






Duration of disease 8.57±9.36 
Site of disease Head & neck 5(17.9%) 
Trunk 3(10.7%) 
Upper limb 1(3.6%) 
Lower limb 2(7.1%) 
Genitalia 1(3.6%) 
Multiple sites 16(57.1%) 
Table 2:Percentage improvement in the disease 
grades of the patients 
Response  No  Percentage  
1. Poor Response 2 7.1 
2. Partial Response 2 7.1 
3. Near Complete 
Response 
4 14.4 
4. Complete Cure 20 71.4 
Table 3:   Impact of demographical variables on 
the study outcome  



















Female 0 0 1 10 11  
0.273 
.0% .0% 25.0% 50.0% 39.3% 
Male 2 2 3 10 17 
100.0% 100.0% 75.0% 50.0% 60.7% 
Age group  2-20 
year 
1 2 2 17 22 0.267 
50.0% 100.0% 50.0% 85.0% 78.6% 
>20 year 1 0 2 3 6 
50.0% .0% 50.0% 15.0% 21.4% 
Table 5).Majority of the patients (82%) tolerated the 
treatment well with no side effects. 2 (7.1%) developed 
contact dermatitis after application of KOH; 3 (10.7%) 
patients developed secondary bacterial infection 
requiring oral antibiotic therapy. Four patients 
developed transient post-inflammatory 
hypopigmentation once the lesions cleared; this 
resolved within a month of stopping KOH 
application.The hypopigmentation settled after the 
completion of study duration with no further 
treatment. 
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Table 4:Stratification of the improvement with 
respect to family history and duration of disease 




















Yes 1 1 1 9 12 0.887 
50.0% 50.0% 25.0% 45.0% 42.9% 
No 1 1 3 11 16 










50.0% .0% 75.0% 95.0% 82.1% 
13-23 
year 
0 2 0 0 2 
.0% 100.0% .0% .0% 7.1% 
>23 year 1 0 1 1 3 
50.0% .0% 25.0% 5.0% 10.7% 
 
Table 5: Improvement according to body site 


























.0% .0% .0% 25.0% 17.9% 
Trunk 0 0 0 3 3 
.0% .0% .0% 15.0% 10.7% 
Upper limb 0 0 0 1 1 
.0% .0% .0% 5.0% 3.6% 
Lower 0 1 0 1 2 
.0% 50.0% .0% 5.0% 7.1% 
Genitalia 0 0 0 1 1 
.0% .0% .0% 5.0% 3.6% 
Multiple sites 2 1 4 9 16 











MC is a common viral infection that frequently affects 
children of school going age. It is thought that using 
community bathing facilities/swimming pools or 
siblings using the same washing sponges or towels 
spreads the infection.11In healthy patients, cutaneous 
MC  is a self-limiting disease that often spontaneously 
resolves in 6 to 9 months, usually without scarring. 
Quality of life is a factor to consider when deciding 
whether or not to treat a paediatric patient as he or she 
may suffer chastisement from peers at school if the 
lesions are visible. Not treating paediatric infections 
also carries the risk of the disease spreading to others, 
and this consideration may favour the option of 
treatment over benign neglect.13  Conditions like atopic 
dermatitis may cause widespread development of MC, 
making it imperative to treat the lesions promptly. 
Destructive treatment options like curettage, 
expression or pricking with a sterile needle, 
electrodessication and laser ablation are not well-
tolerated by children because of pain and are 
expensive. 
Among drugs that are applied topically imiquimod 
has been found to be of limited efficacy. In a study 
spanned over more than 10 yrs in USA it was found 
that it has been prescribed in only 7% of the patients of 
MC.10 KOH has been used in varying strengths; 2.5%, 
5%, 10% and 20%. The rationale for using the lower 
strengths is to minimize its side effects, especially 
reducing irritant effects on face. The exact mechanism 
by which KOH clears MC lesions is not clear. It 
appears that topical application of KOH digests 
keratin and induces inflammation; this in turn 
stimulates innate and cell-mediated immune response 
that inhibits MC-induced immunosuppression and 
eliminates the infection of MC. Considering the same 
mechanism of action KOH has been successfully used 
in warts.14-16 
Short et al, conducted a double blind, randomized, 
placebo-controlled study comparing 10% KOH 
solution with a placebo.17 The end point of their study 
was the complete clearance of the lesions. They 
recruited 20 patients (10 in each group), age ranging 
from 2 – 12 years. They excluded patients with facial 
lesions. 2 (20%) of the patients complained of severe 
stinging sensation and developed severe inflammatory 
response and 2 (20%) reported transient post 
inflammatory hyperpigmentation. 70% of their 
patients’ lesions were cleared with 10% KOH. Only 
20% of the patients in the placebo group cleared the 
lesions at the end of the study. In our study the 
majority of the patients (82%) tolerated the drug well. 
Fig 1:Signs of inflammation 
after application of 10% KOH 
solution 
Fig 2: 6 year old boy, 
baseline 
Fig 3 Same patient, after 2 
weeks of treatment 
 
Fig 4:Same patient, at 8 weeks of 
treatment, mostly resolved lesions, 
2 healed crusted lesions at the base 
of the neck and post inflammatory 
hypopigmentation at few sites 
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7% developed contact dermatitis at the site of 
application but it was easily managed by the use of 
low potency topical steroids. 
 In a similar study Handjani et al8 compared 10% KOH 
with cryotherapy, whose efficacy for treating MC is 
well established. The two groups had 15 patients each. 
Age varied from 1 – 24 years. 86.6% in the KOH group 
had complete clearance as compared to 93.3% in the 
cryotherapy group (p>0.05). Post inflammatory 
hyperpigmentation was noticed more commonly with 
cryotherapy.  
A study on 2 different concentrations of KOH (2.5% 
and 5%) was conducted.18 out of the 29 patients 
recruited in the study 25 completed it; 13 in 2.5% 
group and 12 in 5% group. 11 (44%) of the patients had 
lesional clearance at the end of the study. 8 of these 
patients were in the 5% treatment group and 3 were in 
the 2.5% KOH group. This difference was statistically 
significant (p < 0.047). There were no statistical 
differences between the two groups with respect to 
side-effects (p = 0.682). We have used higher 
percentage 10% KOH solution and achieved better 
efficacy. We would suggest against using 
concentration of KOH lesser than 10%.Al Sudanyet 
al19have compared 10% KOH with 25% podophyllin 
solution. They found 64% of their patients were 
cleared of MC lesions at the end of the study. 
However, the study duration was 4 weeks. We present 
the case that had their patients continued the 
medication the percentage of patients cleared of MC 
could have increased.  
In Pakistan, Qureshi et al have used 10% KOH to treat 
their MC patients. 20 They have compared its efficacy 
with cryotherapy. The mean age of their patients was 
20.53 years. A later incidence peak in young adults is 
attributable to sexual transmission with lesions more 
common in genital area.21 80% of their patients 
achieved clinical clearance of the lesions. They did not 
find statistically significant difference in the clearance 
of the lesions amongst the patients receiving two 
different treatment modalities, indicating 10% KOH 
has the same efficacy as cryotherapy. The patients in 
our study were predominantly children, unlike their 
study based mainly on adults. Therefore, our study 
sheds light on how 10% KOH solution treats children, 
the age group mainly affected by MC.  
Side effects like severe stinging sensation and 
hypopigmentation has been reported with 10% KOH 
use.22In our study 82% of the patients tolerated the 
topical medicament well. Only a few patients 
developed contact dermatitis, secondary infection and 
hypopigmentation at the site which resolved with the 
passage of time. In contrast, destructive therapies like 
cryotherapy and electrodessication are associated with 
much higher chances of burning, pain and pigmentary 
changes which can last for a long time.23-25In our setup 
where patients come from far flung areas, it is difficult 
for them to have regular follow up for hospital based 
treatment. A treatment modality which is economical, 
acceptable, efficacious and easily tolerated is the need 
of the hour.  
Conclusion 
1.10% KOH solution is an effective treatment for MC. 
2. It has the advantage of ease of application at home 
making it a good and feasible option in the treatment 
of MC. 
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